Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

被引：0
|
作者：
Cindy L. J. Weinstein
Alan G. Meehan
Jianxin Lin
Steven D. Briscoe
Marinella Govoni
机构：
[1] Merck & Co.,
[2] Inc,undefined
[3] MSD Italy,undefined
来源：
Clinical Rheumatology | 2023年 / 42卷
关键词：
Golimumab; TNF-α; Treatment persistence; Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3397 / 3405
页数：8
相关论文
共 50 条
  • [41] Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
    Fleischmann, Roy
    Blanco, Ricardo
    van den Bosch, Filip
    Bessette, Louis
    Song, Yanna
    Penn, Sara K.
    McDearmon-Blondell, Erin
    Khan, Nasser
    Chan, Kelly
    Mysler, Eduardo
    RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 599 - 615
  • [42] Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trial
    Berenbaum, Francis
    Thao Pham
    Claudepierre, Pascal
    de Chalus, Thibault
    Joubert, Jean-Michel
    Saadoun, Carine
    Franca, Lionel Riou
    Fautrel, Bruno
    JOINT BONE SPINE, 2018, 85 (01) : 54 - 59
  • [43] Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
    Chandran, Vinod
    van der Heijde, Desiree
    Fleischmann, Roy M.
    Lespessailles, Eric
    Helliwell, Philip S.
    Kameda, Hideto
    Burgos-Vargas, Ruben
    Erickson, Janelle S.
    Rathmann, Suchitrita S.
    Sprabery, Aubrey Trevelin
    Birt, Julie A.
    Shuler, Catherine L.
    Gallo, Gaia
    RHEUMATOLOGY, 2020, 59 (10) : 2774 - 2784
  • [44] Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
    Tsutomu Takeuchi
    Yoshiya Tanaka
    Sakae Tanaka
    Atsushi Kawakami
    Yeong-Wook Song
    Yi-Hsing Chen
    Mitsuhiro Rokuda
    Hiroyuki Izutsu
    Satoshi Ushijima
    Yuichiro Kaneko
    Yoshihiro Nakashima
    Teruaki Shiomi
    Emi Yamada
    Arthritis Research & Therapy, 22
  • [45] Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
    Roy M. Fleischmann
    Daniel F. Alvarez
    Amy E. Bock
    Carol Cronenberger
    Ivana Vranic
    Wuyan Zhang
    Rieke Alten
    Arthritis Research & Therapy, 23
  • [46] Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan (vol 22, 47, 2020)
    Takeuchi, Tsutomu
    Tanaka, Yoshiya
    Tanaka, Sakae
    Kawakami, Atsushi
    Song, Yeong-Wook
    Chen, Yi-Hsing
    Rokuda, Mitsuhiro
    Izutsu, Hiroyuki
    Ushijima, Satoshi
    Kaneko, Yuichiro
    Nakashima, Yoshihiro
    Shiomi, Teruaki
    Yamada, Emi
    ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)
  • [47] Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial
    Fleischmann, Roy M.
    Alvarez, Daniel F.
    Bock, Amy E.
    Cronenberger, Carol
    Vranic, Ivana
    Zhang, Wuyan
    Alten, Rieke
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [48] Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study
    Park, Min-Chan
    Matsuno, Hiroaki
    Kim, Jinseok
    Park, Sung-Hwan
    Lee, Sang-Heon
    Park, Yong-Beom
    Lee, Yun Jong
    Lee, Sang-Il
    Park, Won
    Sheen, Dong Hyuk
    Choe, Jung-Yoon
    Choi, Chan-Bum
    Hong, Seung-Jae
    Suh, Chang-Hee
    Lee, Shin-Seok
    Cha, Hoon-Suk
    Yoo, Bin
    Hur, Jin-Wuk
    Kim, Geun-Tae
    Yoo, Wan-Hee
    Baek, Han Joo
    Shin, Kichul
    Shim, Seung Cheol
    Yang, Hyung-In
    Kim, Hyun Ah
    Park, Kyung-Su
    Choi, In Ah
    Lee, Jisoo
    Tomomitsu, Masato
    Shin, Seonghye
    Lee, Jiyoon
    Song, Yeong Wook
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [49] Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study
    Min-Chan Park
    Hiroaki Matsuno
    Jinseok Kim
    Sung-Hwan Park
    Sang-Heon Lee
    Yong-Beom Park
    Yun Jong Lee
    Sang-Il Lee
    Won Park
    Dong Hyuk Sheen
    Jung-Yoon Choe
    Chan-Bum Choi
    Seung-Jae Hong
    Chang-Hee Suh
    Shin-Seok Lee
    Hoon-Suk Cha
    Bin Yoo
    Jin-Wuk Hur
    Geun-Tae Kim
    Wan-Hee Yoo
    Han Joo Baek
    Kichul Shin
    Seung Cheol Shim
    Hyung-In Yang
    Hyun Ah Kim
    Kyung-Su Park
    In Ah Choi
    Jisoo Lee
    Masato Tomomitsu
    Seonghye Shin
    Jiyoon Lee
    Yeong Wook Song
    Arthritis Research & Therapy, 21
  • [50] Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis
    Yamanaka, Hisashi
    Tanaka, Yoshiya
    Hibino, Toshihiko
    Unmesh, Gopalakrishnan
    Shah, Chirag
    Bakhle, Dhananjay
    Stefanidis, Dimitris
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (01) : 108 - 115
12345